Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.
Nine healthy, fertile women were treated for six months with subdermal contraceptive implants of two different sizes containing a potent progestogen, ST-1435. Lipoprotein cholesterol and triglyceride concentrations were not influenced by the treatment. Similarly, the main apolipoproteins in low- and high-density lipoproteins were not changed, which further supports the interpretation that the lipoprotein metabolism is not affected by this type of treatment. An oral glucose tolerance test (OGTT) including insulin determinations was performed in five of the volunteers with the largest implants. Blood glucose and insulin concentrations during the OGTT remained unchanged during treatment, indicating that the treatment with ST-1435 did not affect carbohydrate metabolism.
D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D003271:Contraceptive Agents, Female / Q000494:pharmacology*; D004343:Drug Implants; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D009652:Norpregnenes / Q000494:pharmacology*; D009653:Norprogesterones / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D001786:Blood Glucose; D003271:Contraceptive Agents, Female; D004343:Drug Implants; D007328:Insulin; D008074:Lipoproteins; D009652:Norpregnenes; D009653:Norprogesterones; D014280:Triglycerides; D011374:Progesterone; D004958:Estradiol; C029167:ST 1435; D002784:Cholesterol